metaEvidence - overview

benefit
(statisticaly significant)

benefit (nominaly significant, not statitically demonstrated)

not significant

harm statitically significant

harm not significant

low certainty due to bias


			deaths (OS)	progression or deaths (PFS)	RFS/DFS
mML - NA - all population metastatic/adv melanoma (mML) mML - (neo)adjuvant (NA) mML - NA - all population
versus nivolumab alone
	nivolumab plus ipilimumab vs. nivolumab alone	1	-	-
versus placebo
	nivolumab plus ipilimumab vs. placebo	1	-	-
mML - NA - PDL1 positive metastatic/adv melanoma (mML) mML - (neo)adjuvant (NA) mML - NA - PDL1 positive
mML - L1 - all population metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - all population
versus ipilimumab alone
	nivolumab plus ipilimumab vs. ipilimumab alone	2			-
versus nivolumab alone
	nivolumab plus ipilimumab vs. nivolumab alone	1			-
	relatlimab plus nivolumab vs. nivolumab alone	1	-		-
mML - L1 - BRAF mutant metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF mutant
versus ipilimumab alone
	nivolumab plus ipilimumab vs. ipilimumab alone	1			-
mML - L1 - BRAF wild metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF wild
versus ipilimumab alone
	nivolumab plus ipilimumab vs. ipilimumab alone	1	-		-
mML - L2 - all population metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - all population
mML - L2 - BRAF mutant metastatic/adv melanoma (mML) mML - 2nd line (L2) mML - L2 - BRAF mutant